PuSH - Publikationsserver des Helmholtz Zentrums München

Dislich, B.* ; Stein, A.* ; Seiler, C.A.* ; Kröll, D.* ; Berezowska, S.* ; Zlobec, I.* ; Galvan, J.A.* ; Slotta-Huspenina, J.* ; Walch, A.K. ; Langer, R.*

Expression patterns of programmed death-ligand 1 in esophageal adenocarcinomas: Comparison between primary tumors and metastases.

Cancer Immunol. Immunother. 66, 777-786 (2017)
Postprint DOI PMC
Open Access Green
Expression analysis of programmed death-ligand 1 (PD-L1) may be helpful in guiding clinical decisions for immune checkpoint inhibition therapy, but testing by immunohistochemistry may be hampered by heterogeneous staining patterns within tumors and expression changes during metastatic course. PD-L1 expression (clone SP142) was investigated in esophageal adenocarcinomas using tissue microarrays (TMA) from 112 primary resected tumors, preoperative biopsies and full slide sections from a subset of these cases (n = 24), corresponding lymph node (n = 55) and distant metastases (n = 17). PD-L1 expression was scored as 0.1-1, >1, >5, >50% positive membranous staining of tumor cells and any positive staining of tumor-associated inflammatory infiltrates and/or stroma cells. There was a significant correlation with overall PD-L1 expression between the full slide sections and the TMA (p = 0.001), but not with the corresponding biopsies. PD-L1 expression in tumor cells >1% was detected in 8.0% of cases (9/112) and 51.8% of cases (58/112) in tumor-associated inflammatory infiltrates and/or stroma cells of primary tumors. Epithelial expression in metastases was found in 5.6% of cases (4/72) and immune cell expression in 18.1% of cases (13/72), but did not correlate with the expression pattern in the primary tumor. Overall PD-L1 expression in the primary tumor did not influence survival. However, PD-L1 expression was correlated with the number of CD3(+) tumor-infiltrating lymphocytes in the tumor center, and a combinational score of PD-L1 status/CD3(+) tumor-infiltrating lymphocytes was correlated with patients' overall survival.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Esophageal Adenocarcinoma ; Immunohistochemistry ; Metastases ; Pd-l1; T-cell Apoptosis; Immune Checkpoint; Pd-l1; Cancer; Immunotherapy; Blockade; B7-h1; Immunohistochemistry; Microenvironment; Prognosis
ISSN (print) / ISBN 0340-7004
e-ISSN 1432-0851
Zeitschrift Cancer Immunology, Immunotherapy
Quellenangaben Band: 66, Heft: 6, Seiten: 777-786 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) Research Unit Analytical Pathology (AAP)